AGEM400(HES), a Novel Erythropoietin Mimetic Peptide Conjugated to Hydroxyethyl Starch with Excellent In Vitro Efficacy

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Open Hematology Journal

• Publication date

  2010-09-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/1874276901004010001
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Sentinel Surveillance of Influenza-Like-Illness in Two Cities of the Tropical Country of Ecuador: 2006–2010

  2011cited by this paper
• Modern Rapidly Degradable Hydroxyethyl Starches: Current Concepts

  2009cited by this paper
• PEG-modified biopharmaceuticals.

  2009cited by this paper
• Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications.

  2009cited by this paper
• A Phase I, Single and Fractionated, Ascending‐Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of an Erythropoietin Mimetic Antibody Fusion Protein (CNTO 528) in Healthy Male Subjects

  2008cited by this paper
• Erythropoietins: a common mechanism of action.

  2008cited by this paper
• Preclinical Safety and Pharmacology of Hematide™, a Peptidic Erythropoiesis Stimulating Agent (ESA), in Rats and Monkeys

  2008cited by this paper
• Polymer conjugates as therapeutics: future trends, challenges and opportunities.

  2008cited by this paper
• CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice.

  2008cited by this paper
• Preclinical safety and pharmacology of Hematide, a peptidic erythropoiesis stimulating agent (ESA), in rats and monkeys.

  2008influential reference
• Developments in the therapeutic use of erythropoiesis stimulating agents

  2008cited by this paper
• Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model.

  2007cited by this paper
• HES 130/0.42 shows less alteration of pharmacokinetics than HES 200/0.5 when dosed repeatedly.

  2007cited by this paper
• Multivalency—a way to enhance binding avidities and bioactivity—preliminary applications to EPO

  2007cited by this paper
• PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies

  2007cited by this paper
• Pharmacodynamics and organ storage of hydroxyethyl starch in acute hemodilution in pigs: Influence of molecular weightand degree of substitution

  2007cited by this paper
• Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

  2006cited by this paper
• Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.

  2006influential reference
• Recent advances in erythropoietic agents in renal anemia.

  2006cited by this paper
• Chronic Preclinical Safety Evaluation of Hematide™, a PEGylated Peptidic Erythropoiesis Stimulating Agent, in Monkeys.

  2006influential reference
• What is antibody-mediated pure red cell aplasia (PRCA)?

  2005cited by this paper
• Immunologic mechanisms of EPO-associated pure red cell aplasia.

  2005cited by this paper
• CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.

  2005influential reference
• Control of rHuEPO biological activity: the role of carbohydrate.

  2004cited by this paper
• Hydroxyethyl starch – can the safety problems be ignored?

  2004cited by this paper
• Hydroxyethyl starch – can the safety problems be ignored?

  2004cited by this paper
• Tissue Storage of 14C-Labelled Hydroxyethyl Starch (HES) 130/0.4 and HES 200/0.5 after Repeated Intravenous Administration to Rats

  2003cited by this paper
• The Pharmacokinetics and Tolerability of an Intravenous Infusion of the New Hydroxyethyl Starch 130/0.4 (6%, 500 mL) in Mild-to-Severe Renal Impairment

  2002cited by this paper
• Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

  2001cited by this paper
• Pharmacokinetics and Tolerability of a New Hydroxyethyl Starch (HES) Specification [HES (130/0.4] after Single-Dose Infusion of 6% or 10% Solutions in Healthy Volunteers

  1998cited by this paper
• Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1.

  1998influential reference
• Increased potency of an erythropoietin peptide mimetic through covalent dimerization

  1997influential reference
• Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity.

  1997cited by this paper
• In vitro bioassay for human erythropoietin based on proliferative stimulation of an erythroid cell line and analysis of carbohydrate-dependent microheterogeneity.

  1996cited by this paper
• Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin

  1996influential reference
• Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice.

  1994cited by this paper
• Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7.

  1993cited by this paper
• Polyethylene glycol (PEG)-modified granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved biological activity.

  1992cited by this paper
• Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granulocyte-macrophage colony-stimulating factor, interleukin 3, or erythropoietin for growth and survival.

  1991cited by this paper
• Establishment and characterization of a unique human cell line that proliferates dependently on GM‐CSF, IL‐3, or erythropoietin

  1989cited by this paper

• Identification of erythropoietin mimetic peptide 1 linear form in a sealed vial and its administration study in horses for doping control purpose.

  2023cites this paper
• Microbial Transglutaminase-Mediated Formation of Erythropoietin-Polyester Conjugates.

  2022cites this paper
• Advances in thermoplastic starch-based biopolymers: Fabrication and improvement

  2021cites this paper
• Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges.

  2019cites this paper
• Polysaccharides for protein and peptide conjugation

  2019cites this paper
• Colloidal hydroxyethyl starch for tumor-targeted platinum delivery

  2018cites this paper
• iRGD-decorated reduction-responsive nanoclusters for targeted drug delivery.

  2018cites this paper
• Erythropoietin mimetic peptides and erythropoietin fusion proteins for treating anemia of chronic kidney disease

  2018cites this paper
• Biodegradable Polymers for Protein and Peptide Therapeutics: Next Generation Delivery Systems

  2017cites this paper
• New Treatment Approaches for the Anemia of CKD.

  2016cites this paper
• Half‐Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation

  2016cites this paper
• Efficient soluble expression of two copies of EMP1 connected in series in Escherichia coli, with enhanced EPO activity

  2015cites this paper
• EPOR-Based Purification and Analysis of Erythropoietin Mimetic Peptides from Human Urine by Cys-Specific Cleavage and LC/MS/MS

  2015cites this paper
• Head to head comparison of the formulation and stability of concentrated solutions of HESylated versus PEGylated anakinra.

  2015cites this paper
• Formulation of PEGylated and HESylated biopharmaceuticals

  2015cites this paper
• Protein HESylation for half-life extension: synthesis, characterization and pharmacokinetics of HESylated anakinra.

  2014cites this paper
• Structural Modification of Proteins and Peptides

  2014cites this paper
• Erythropoietin mimetic compound AGEM400(HES) binds to the same receptor as erythropoietin but displays a different spectrum of activities.

  2012cites this paper
• Zell- und molekularbiologische Untersuchungen eines EPO-mimetischen Peptides während der präklinischen Phase der Arzneimittelentwicklung

  2010cites this paper